New drug cocktail aims to control advanced breast cancer
NCT ID NCT05508906
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 30 times
Summary
This early-phase study is testing a new drug called OP-1250 (palazestrant) combined with other targeted therapies for people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find the safest dose and understand side effects. About 190 adults will participate in one of four treatment groups, each pairing OP-1250 with a different drug (ribociclib, alpelisib, everolimus, or atirmociclib). This is not a cure; it aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advent Health Hematology and Oncology
RECRUITINGOrlando, Florida, 32804, United States
Contact
-
Atrium Health Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact
-
Banner MD Anderson Cancer Center
RECRUITINGGilbert, Arizona, 85234, United States
Contact
-
Breast Cancer Research Center- Western Australia
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
-
Henry Ford Health
RECRUITINGDetroit, Michigan, 48126, United States
Contact
-
Henry-Joyce Cancer Clinic, The Vanderbilt Clinic
RECRUITINGNashville, Tennessee, 37232, United States
Contact
-
Ichan School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Macquarie Health
RECRUITINGSydney, New South Wales, 2109, Australia
Contact
-
Northwest Medical Specialties
RECRUITINGTacoma, Washington, 98405, United States
Contact
-
Regents of the University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact
-
University of California San Francisco Health
RECRUITINGSan Francisco, California, 94158, United States
Contact
-
University of Colorado Cancer Center
RECRUITINGAurora, Colorado, 80045, United States
Contact
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
Contact
-
Washington University, School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Conditions
Explore the condition pages connected to this study.